GlassScriptPhysician profile
Eleanor G Smith
NPI 1942459292
$1,072.20
in general payments reported to CMS, 2019-2025
20 companies · $392 in 2025
The $392 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43.87 · 2023: $177 · 2024: $459 · 2025: $392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,028.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,028.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $122.80 | 2024-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $104.06 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $90.97 | 2023-2025 | Shingrix, Arexvy |
| Pfizer INC. | $86.39 | 2024-2025 | |
| Abbvie INC. | $81.09 | 2023-2025 | Viberzi, Linzess |
| Exact Sciences Corporation | $65.42 | 2023-2025 | Cologuard Collection Kit |
| Paratek Pharmaceuticals, INC. | $62.27 | 2024-2025 | Nuzyra |
| Amgen INC. | $58.76 | 2024-2025 | Evenity, Prolia, Prolia |
| Astellas Pharma US INC | $48.03 | 2024 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.61 | 2024-2025 | Xifaxan, Relistor |
| Depuy Synthes Sales INC. | $43.87 | 2019 | |
| Merck Sharp & Dohme LLC | $39.45 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Rgh Enterprises LLC | $39.07 | 2025 | |
| Hikma Pharmaceuticals USA | $37.97 | 2024-2025 | Ryaltris, Kloxxado |
| Novo Nordisk INC | $36.91 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $24.65 | 2025 | |
| Bausch Health US, LLC | $23.46 | 2023 | Aplenzin |
| Axsome Therapeutics, INC. | $23.31 | 2024 | Sunosi |
| Abbott Laboratories | $23.09 | 2023 | Proclaim |
| Idorsia Pharmaceuticals US INC | $14.02 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eleanor Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.